KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $7.8 million.

  • Supernus Pharmaceuticals' Share-based Compensation rose 196.77% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 1680.22%. This contributed to the annual value of $27.8 million for FY2024, which is 372.21% up from last year.
  • Supernus Pharmaceuticals' Share-based Compensation amounted to $7.8 million in Q3 2025, which was up 196.77% from $7.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Share-based Compensation's 5-year high stood at $8.1 million during Q1 2025, with a 5-year trough of $4.0 million in Q1 2022.
  • For the 5-year period, Supernus Pharmaceuticals' Share-based Compensation averaged around $6.0 million, with its median value being $6.1 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 2153.03% in 2022, then skyrocketed by 5887.66% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Share-based Compensation (Quarter) stood at $4.0 million in 2021, then grew by 5.57% to $4.3 million in 2022, then skyrocketed by 51.26% to $6.4 million in 2023, then increased by 18.42% to $7.6 million in 2024, then grew by 2.53% to $7.8 million in 2025.
  • Its Share-based Compensation was $7.8 million in Q3 2025, compared to $7.5 million in Q2 2025 and $8.1 million in Q1 2025.